Literature DB >> 21948959

Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry.

P Gabriel Steg1, Samir Alam, Chern-En Chiang, Habib Gamra, Marnix Goethals, Hiroshi Inoue, Laura Krapf, Thorsten Lewalter, Ihsen Merioua, Jan Murin, Lisa Naditch-Brûlé, Piotr Ponikowski, Mårten Rosenqvist, José Silva-Cardoso, Oleg Zharinov, Sandrine Brette, James O Neill.   

Abstract

BACKGROUND: Rate control and rhythm control are accepted management strategies for atrial fibrillation (AF).
OBJECTIVE: RealiseAF aimed to describe the success of either strategy and the impact of control on symptomatic status of patients with AF.
METHODS: This international, observational, cross-sectional survey of patients with any history of AF in the previous year, recorded AF characteristics, management and frequency of control (defined as sinus rhythm or AF with resting heart rate ≤80 bpm).
RESULTS: Overall, 9665 patients were evaluable for AF control, with 59.0% controlled (sinus rhythm 26.5%, AF ≤80 bpm 32.5%) and 41.0% uncontrolled. Symptom prevalence in the previous week was lower in controlled than uncontrolled AF (55.7% vs 68.4%; p<0.001) and similar for patients in sinus rhythm versus AF ≤80 bpm (54.8% vs 56.4%; p=0.23). At the visit, AF-related functional impairment (EHRA class >I) was seen in 67.4% of patients with controlled AF and 82.1% of patients with uncontrolled AF (p<0.001). Quality-of-life (QoL, measured using EQ-5D) was better for patients with controlled versus uncontrolled AF using the Visual Analogue Scale (mean (SD) score 67.1 (18.4) vs 63.2 (18.9); p<0.001), single index utility score (median 0.78 vs 0.73; p<0.001), or five dimensions of well-being (all p<0.001). Irrespective of AF control, cardiovascular events had led to hospitalisation in the past year in 28.1%.
CONCLUSION: AF control is not optimal. Control appears to be associated with fewer symptoms and better QoL, but even patients with controlled AF have frequent symptoms, functional impairment, altered QoL and cardiovascular events. New treatments are needed to improve control and minimise the functional and QoL burden of AF.

Entities:  

Mesh:

Year:  2011        PMID: 21948959     DOI: 10.1136/heartjnl-2011-300550

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  37 in total

1.  Rate versus rhythm in atrial fibrillation: and how slow do you go?

Authors:  G Michael Allan; Christina Korownyk; Michael R Kolber
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2013-09-24       Impact factor: 4.749

Review 4.  Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review.

Authors:  Kelly T Gleason; Saman Nazarian; Cheryl R Dennison Himmelfarb
Journal:  J Cardiovasc Nurs       Date:  2018 Mar/Apr       Impact factor: 2.083

5.  Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation.

Authors:  Evan L Thacker; Barbara McKnight; Bruce M Psaty; W T Longstreth; Sascha Dublin; Paul N Jensen; Katherine M Newton; Nicholas L Smith; David S Siscovick; Susan R Heckbert
Journal:  J Gen Intern Med       Date:  2012-09-13       Impact factor: 5.128

Review 6.  Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions.

Authors:  Steven T Heidt; Anna Kratz; Kayvan Najarian; Afton L Hassett; Hakan Oral; Richard Gonzalez; Brahmajee K Nallamothu; Daniel Clauw; Hamid Ghanbari
Journal:  J Atr Fibrillation       Date:  2016-06-30

7.  Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Benjamin A Steinberg; DaJuanicia N Holmes; Michael D Ezekowitz; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Paul Chang; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2013-02-20       Impact factor: 4.749

8.  Development and validation of the AFSymp™: an atrial fibrillation-specific measure of patient-reported symptoms.

Authors:  Jennie Medin; Rob Arbuckle; Linda Abetz; Katarina Halling; Karoly Kulich; Nils Edvardsson; Karin S Coyne
Journal:  Patient       Date:  2014       Impact factor: 3.883

9.  Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Jacqueline Rimmler; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  J Atr Fibrillation       Date:  2014-06-30

Review 10.  The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.

Authors:  Xiaohan Fan; Shu Zhang
Journal:  J Atr Fibrillation       Date:  2014-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.